Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation
NCT ID: NCT05207644
Last Updated: 2022-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2021-12-09
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks
NCT02720991
Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages
NCT05304273
The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy
NCT05341817
Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy
NCT01475318
Letrozole and Misoprostol for Early Pregnancy Loss Management
NCT06452719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Letrozole followed by misoprostol
There is only one arm in this study.
30 mg letrozole followed by 800 mcg misoprostol
30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
30 mg letrozole followed by 800 mcg misoprostol
30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pregnancy visible on ultrasound
* Speaks English or Spanish
* Willing and able to return for follow-up appointment
Exclusion Criteria
* Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass
* Pregnancy of unknown location
* IUD or contraceptive implant in place
* History of allergy to letrozole or misoprostol
* Unable to return for clinic-based follow-up
* Currently breastfeeding
* Twin or multiple pregnancy
* History of liver disease or abnormal liver function
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gynuity Health Projects
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tara Shochet, PhD, MPH
Role: PRINCIPAL_INVESTIGATOR
Gynuity Health Projects
Beverly Winikoff, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Gynuity Health Projects
David Turok, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
The University of Utah
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Planned Parenthood Salt Lake Health Center
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.